Sp465

PANEL DISCUSSION

Date
May 7, 2023
Explore related products in the following collection:

Society: AGA

In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.

Presenters

Speaker Image for Sunanda Kane
Mayo Clinic
Speaker Image for Uma Mahadevan
University of California san francisco
Speaker Image for Edward Loftus
Mayo Foundation for Medical Education and Research
Speaker Image for Ashwin Ananthakrishnan
Massachusetts General Hospital

Tracks

Related Products

Thumbnail for SINGLE-CELL AND SPATIAL MULTI-OMICS IDENTIFY INNATE AND STROMAL MODULES TARGETED BY ANTI-INTEGRIN THERAPY IN ULCERATIVE COLITIS
SINGLE-CELL AND SPATIAL MULTI-OMICS IDENTIFY INNATE AND STROMAL MODULES TARGETED BY ANTI-INTEGRIN THERAPY IN ULCERATIVE COLITIS
BACKGROUND: Mesenteric fat is increasingly believed to exert an important influence on intestinal inflammation. A hallmark of severe Crohn's disease (CD) is the accumulation of mesenteric fat around the inflamed intestine, typically in the terminal ileum…
Thumbnail for INTERACTIONS BETWEEN HOST DIETARY INTAKE AND GUT MICROBIAL TRANSCRIPTION IN INFLAMMATORY BOWEL DISEASE
INTERACTIONS BETWEEN HOST DIETARY INTAKE AND GUT MICROBIAL TRANSCRIPTION IN INFLAMMATORY BOWEL DISEASE
The microbiome plays a central role in intestinal inflammation in IBD. It is influenced by environmental factors included diet…
Thumbnail for INFLAMMATORY BOWEL DISEASE AND THE RISK OF ANAL DYSPLASIA AND CANCER AMONG MEN WHO HAVE SEX WITH MEN
INFLAMMATORY BOWEL DISEASE AND THE RISK OF ANAL DYSPLASIA AND CANCER AMONG MEN WHO HAVE SEX WITH MEN
BACKGROUND: The impact of pregnancy on vedolizumab (VDZ) and ustekinumab (UST) pharmacokinetics is not well defined. Similarly, the time to infant clearance and outcomes following in-utero exposure require elucidation…